Published in J Immunol on November 01, 2004
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
Proteasome regulation of ULBP1 transcription. J Immunol (2009) 1.61
Regulation of ligands for the activating receptor NKG2D. Immunology (2007) 1.55
Cutting edge: down-regulation of MHC class I-related chain A on tumor cells by IFN-gamma-induced microRNA. J Immunol (2009) 1.30
Role of NF-kappaB-dependent caveolin-1 expression in the mechanism of increased endothelial permeability induced by lipopolysaccharide. J Biol Chem (2007) 1.25
NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. J Immunol (2007) 1.14
Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr Opin Immunol (2015) 1.10
The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. Front Immunol (2014) 1.02
NF-κB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site. J Biol Chem (2011) 1.00
Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia (2012) 0.93
Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. Curr Immunol Rev (2009) 0.91
Gender-specific associations between MICA-STR and nasopharyngeal carcinoma in a southern Chinese Han population. Immunogenetics (2006) 0.90
Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-γ in experimental dry eye. J Immunol (2014) 0.87
Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb Symp Quant Biol (2013) 0.86
NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses. Front Immunol (2013) 0.86
Insights on glucocorticoid receptor activity modulation through the binding of rigid steroids. PLoS One (2010) 0.83
MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int (2011) 0.82
Heightened expression of MICA enhances the cytotoxicity of NK cells or CD8+T cells to human corneal epithelium in vitro. BMC Ophthalmol (2012) 0.80
Broad MICA/B expression in the small bowel mucosa: a link between cellular stress and celiac disease. PLoS One (2013) 0.80
Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA. Int J Hyperthermia (2013) 0.80
NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells. Cancer Immunol Immunother (2015) 0.79
Genotyping and segregation analyses indicate the presence of only two functional MIC genes in rhesus macaques. Immunogenetics (2007) 0.78
Viral IL-10 down-regulates the "MHC-I antigen processing operon" through the NF-κB signaling pathway in nasopharyngeal carcinoma cells. Cytotechnology (2016) 0.78
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene (2016) 0.77
MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant (2016) 0.76
IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol (2009) 0.76
Xanthine oxidoreductase is required for genotoxic stress-induced NKG2D ligand expression and gemcitabine-mediated antitumor activity. Oncotarget (2016) 0.75
Pas de deux: natural killer receptors and MHC class I ligands in primates. Curr Genomics (2007) 0.75
Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer Treatment. Clin Cancer Res (2016) 0.75
The nuclear factor-κB pathway down-regulates expression of the NKG2D ligand H60a in vitro: implications for use of nuclear factor-κB inhibitors in cancer therapy. Immunology (2013) 0.75
Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5.30
Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol (2007) 3.07
Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol (2008) 2.77
Galectins: structure, function and therapeutic potential. Expert Rev Mol Med (2008) 2.61
Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell (2004) 2.46
A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology (2007) 2.45
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A (2007) 2.31
Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol (2009) 2.23
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity (2012) 2.18
A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med (2007) 2.08
Galectins: regulators of acute and chronic inflammation. Ann N Y Acad Sci (2010) 1.83
A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res (2012) 1.74
Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction. J Immunol (2007) 1.61
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood (2011) 1.53
A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol (2007) 1.46
Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res (2012) 1.44
Galectin-1 suppresses experimental colitis in mice. Gastroenterology (2003) 1.41
Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol (2006) 1.37
When galectins recognize glycans: from biochemistry to physiology and back again. Biochemistry (2011) 1.34
Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med (2012) 1.31
Galectin-3 mediates IL-4-induced survival and differentiation of B cells: functional cross-talk and implications during Trypanosoma cruzi infection. J Immunol (2004) 1.24
NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin Dev Immunol (2010) 1.21
Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother (2007) 1.21
Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol (2007) 1.20
Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology (2004) 1.18
Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J Immunol (2008) 1.17
Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem (2004) 1.17
Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol (2007) 1.14
AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res (2008) 1.11
Cancer vaccines: an update with special focus on ganglioside antigens. Oncol Rep (2002) 1.10
Control of dendritic cell maturation and function by triiodothyronine. FASEB J (2007) 1.06
Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J Virol (2006) 1.06
Fucans, but not fucomannoglucuronans, determine the biological activities of sulfated polysaccharides from Laminaria saccharina brown seaweed. PLoS One (2011) 1.05
Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J Cell Biochem (2008) 1.05
Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer (2011) 1.03
Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother (2006) 1.03
Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression. J Leukoc Biol (2011) 1.02
Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. Arthritis Rheum (2009) 1.02
Activation-induced expression of MICA on T lymphocytes involves engagement of CD3 and CD28. J Leukoc Biol (2002) 1.01
Endogenous lectins shape the function of dendritic cells and tailor adaptive immunity: mechanisms and biomedical applications. Int Immunopharmacol (2011) 1.01
Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev (2007) 0.99
Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J (2010) 0.98
Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep (2007) 0.97
Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res (2009) 0.96
Multiple functional targets of the immunoregulatory activity of galectin-1: Control of immune cell trafficking, dendritic cell physiology, and T-cell fate. Methods Enzymol (2010) 0.96
Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev (2013) 0.95
Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother (2012) 0.95
Apoptosis resistance in HIV-1 persistently-infected cells is independent of active viral replication and involves modulation of the apoptotic mitochondrial pathway. Retrovirology (2008) 0.95
Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood (2011) 0.95
Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer. Expert Opin Biol Ther (2008) 0.95
Expression of signaling lymphocytic activation molecule-associated protein interrupts IFN-gamma production in human tuberculosis. J Immunol (2004) 0.93
Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology (2002) 0.93
Nuclear factor (NF)-kappaB-dependent thyroid hormone receptor beta1 expression controls dendritic cell function via Akt signaling. J Biol Chem (2009) 0.93
Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother (2004) 0.93
Expanding the universe of cytokines and pattern recognition receptors: galectins and glycans in innate immunity. J Clin Immunol (2010) 0.92
Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology (2011) 0.92
Coupling pathogen recognition to innate immunity through glycan-dependent mechanisms. Int Immunopharmacol (2011) 0.91
The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J (2007) 0.91
Unlocking the secrets of galectins: a challenge at the frontier of glyco-immunology. J Leukoc Biol (2002) 0.91
Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol (2006) 0.90
Bone-specific antibodies in sera from patients with celiac disease: characterization and implications in osteoporosis. J Clin Immunol (2002) 0.90
Regulated expression of galectin-3, a multifunctional glycan-binding protein, in haematopoietic and non-haematopoietic tissues. Histol Histopathol (2011) 0.90
NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J Immunol (2008) 0.90
Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity? Cytokine Growth Factor Rev (2007) 0.90
Regulated expression and ultrastructural localization of galectin-1, a proapoptotic beta-galactoside-binding lectin, during spermatogenesis in rat testis. Biol Reprod (2003) 0.90
Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation (2010) 0.89
Imatinib resistance in multidrug-resistant K562 human leukemic cells. Leuk Res (2008) 0.89
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells. Curr Pharm Des (2010) 0.88
Simultaneous expression of Th1 cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children. Hum Immunol (2004) 0.88
Suprachiasmatic astrocytes as an interface for immune-circadian signalling. J Neurosci Res (2006) 0.88
Characterization and functionality of proliferative human Sertoli cells. Cell Transplant (2010) 0.88
Regulation of galectin-1 expression by transforming growth factor beta1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother (2006) 0.87
Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis. Invest Ophthalmol Vis Sci (2005) 0.87
Nuclear factor (NF)-κB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol Immunol (2011) 0.87
Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands. EMBO Rep (2009) 0.86
Galectin-1 controls cardiac inflammation and ventricular remodeling during acute myocardial infarction. Am J Pathol (2012) 0.86
Dexamethasone counteracts the immunostimulatory effects of triiodothyronine (T3) on dendritic cells. Steroids (2011) 0.86
RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis. FEBS Lett (2007) 0.86
Interstrain differences in chronic hepatitis and tumor development in a murine model of inflammation-mediated hepatocarcinogenesis. Hepatology (2013) 0.86
Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur J Immunol (2013) 0.86
Regulated expression of galectin-1 during T-cell activation involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase and p70S6 kinase. Mol Cell Biochem (2004) 0.85
Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol (2003) 0.85
Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development. PLoS One (2012) 0.85